Tag: European Commission
European Commission Grants Conditional Marketing Authorization to GSK for the Use...
The European Commission has granted conditional marketing authorization* for the use of GlaxoSmithKline's anti-B-cell maturation antigen (BCMA) therapy belantamab mafodotin (Blenrep®) as monotherapy for...
Brentuximab Vedotin Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma...
The European Commission has extended the current conditional marketing authorization for brentuximab vedotin (Adcetris®; Takeda/Seattle Genetics) to include the treatment of adult patients with...
European Commission Approves Label Variation for Brentuximab Vedotin
The European Commission (EC) has, earlier this week, approved a Type II variation for brentuximab vedotin (Adcetris®; Takeda/Seattle Genetics) to include data on the...
